About this FactMed analysis covering adverse side effect reports of ALIZAPRIDE patients who developed THROMBOCYTOPENIA.

FactMed provides MD-approved analysis to help both patients, researchers, and physicians accurately assess the risk profile for more than 20,000 different pharmaceutical products. The below report offers compiled information from Food & Drug Administration and FactMed user submissions. Between January 2004 and October 2012, 4 individuals taking ALIZAPRIDE reported THROMBOCYTOPENIA to the FDA. A total of 102 ALIZAPRIDE drug adverse event reaction reports were made with the FDA during this time period. Often the FDA only receives reports of the most critical and severe cases; these numbers may therefore underrepresent the complication rate of the medication.

FDA Research Report

Introduction This page is designed to help you determine the relationship, if any, between ALIZAPRIDE and THROMBOCYTOPENIA. In doing so, we compare ALIZAPRIDE with other drugs that cause THROMBOCYTOPENIA, to help you evaluate whether or not ALIZAPRIDE causes THROMBOCYTOPENIA. Likewise, this page shows the most highly-reported side effects of ALIZAPRIDE, so you can see if THROMBOCYTOPENIA ranks among ALIZAPRIDE's most well-known side effects.
Summary Statistics
Reports of ALIZAPRIDE causing THROMBOCYTOPENIA: 4
Reports of any side effect of ALIZAPRIDE : 102
Percentage of ALIZAPRIDE patients where THROMBOCYTOPENIA is a reported side effect: 3.9216%

FDA reports of any drug causing THROMBOCYTOPENIA : 37390
Average percentage for all medicated patients where THROMBOCYTOPENIA is reported as a complication: 0.2343%

Physician opinion on ALIZAPRIDE as adverse event culprit:

Overall opinion for all reports of this drug:
Most frequent diagnoses/indications for prescribing ALIZAPRIDE:
DRUG USE FOR UNKNOWN INDICATION ( 14 patients )
NAUSEA ( 14 patients )
PRODUCT USED FOR UNKNOWN INDICATION ( 3 patients )
PREMEDICATION ( 2 patients )
VOMITING ( 2 patients )
ANTIEMETIC SUPPORTIVE CARE ( 2 patients )
PROPHYLAXIS ( 1 patients )
PROPHYLAXIS OF NAUSEA AND VOMITING ( 1 patients )
( 0 patients )
Drugs with high FDA adverse event association with THROMBOCYTOPENIA:

HEPARIN SODIUM INJECTION (4057 patients)
ASPIRIN (3010 patients)
REVLIMID (2931 patients)
DEXAMETHASONE (2402 patients)
LASIX (2000 patients)
PREDNISONE (1949 patients)
OMEPRAZOLE (1689 patients)
NPLATE (1653 patients)
CYCLOPHOSPHAMIDE (1515 patients)
VELCADE (1495 patients)
ACETAMINOPHEN (1483 patients)
ZOMETA (1451 patients)
CISPLATIN (1433 patients)
CARBOPLATIN (1423 patients)
FUROSEMIDE (1327 patients)
ALLOPURINOL (1293 patients)
METHOTREXATE (1215 patients)
HEPARIN (1202 patients)
FOLIC ACID (1184 patients)
PREDNISOLONE (1095 patients)
NEXIUM (1091 patients)
FLUOROURACIL (1068 patients)
POTASSIUM CHLORIDE (957 patients)
LOVENOX (939 patients)
COUMADIN (932 patients)
LISINOPRIL (931 patients)
SIMVASTATIN (918 patients)
PLAVIX (908 patients)
ZOFRAN (902 patients)
AREDIA (892 patients)
PROTONIX (889 patients)
DECADRON (880 patients)
VIOXX (877 patients)
LIPITOR (872 patients)
VANCOMYCIN (869 patients)
RITUXIMAB (857 patients)
PREDNISONE TAB (847 patients)
ETOPOSIDE (805 patients)
ACYCLOVIR (800 patients)
CYTARABINE (783 patients)
FOSAMAX (771 patients)
DIGOXIN (733 patients)
FLUCONAZOLE (730 patients)
VINCRISTINE (721 patients)
ATENOLOL (717 patients)
LEVOTHYROXINE SODIUM (717 patients)
KEPPRA (709 patients)
OXYCONTIN (703 patients)
PRILOSEC (689 patients)
HEPARIN SODIUM (674 patients)
AMBIEN (673 patients)
NEUPOGEN (672 patients)
ARANESP (660 patients)
DOXORUBICIN HCL (659 patients)
LORAZEPAM (658 patients)
MORPHINE (657 patients)
GLEEVEC (652 patients)
BACTRIM (650 patients)
OXALIPLATIN (643 patients)
SUTENT (642 patients)
ATIVAN (640 patients)
SYNTHROID (629 patients)
XANAX (619 patients)
NEURONTIN (611 patients)
NORVASC (611 patients)
GEMCITABINE (605 patients)
WARFARIN SODIUM (604 patients)
REMICADE (587 patients)
CYCLOSPORINE (586 patients)
THALIDOMIDE (585 patients)
LEVAQUIN (585 patients)
RIBAVIRIN (576 patients)
ALBUTEROL (573 patients)
PEGASYS (572 patients)
CIPROFLOXACIN (568 patients)
COMPAZINE (568 patients)
GEMZAR (554 patients)
EXJADE (554 patients)
IBUPROFEN (552 patients)
GABAPENTIN (549 patients)
HYDROCHLOROTHIAZIDE (542 patients)
SOLU-MEDROL (541 patients)
OXYCODONE HCL (532 patients)
SEROQUEL (531 patients)
METHYLPREDNISOLONE (524 patients)
METOPROLOL TARTRATE (520 patients)
INSULIN (519 patients)
ZOCOR (510 patients)
ONDANSETRON (496 patients)
VICODIN (492 patients)
LYRICA (488 patients)
PANTOPRAZOLE (488 patients)
AVASTIN (485 patients)
DIFLUCAN (482 patients)
LANSOPRAZOLE (479 patients)
AMLODIPINE (477 patients)
FAMOTIDINE (476 patients)
RAMIPRIL (473 patients)
VIDAZA (473 patients)
MULTI-VITAMINS (472 patients)
ZOLOFT (471 patients)
CORTICOSTEROIDS (468 patients)
PERCOCET (464 patients)
CLOZARIL (464 patients)
METFORMIN HCL (458 patients)
RISPERDAL (457 patients)
FENTANYL (452 patients)
ZYVOX (450 patients)
AUGMENTIN '125' (448 patients)
RANITIDINE (444 patients)
PACLITAXEL (439 patients)
PREVACID (436 patients)
XELODA (435 patients)
ENOXAPARIN SODIUM (431 patients)
TOPROL-XL (431 patients)
VITAMIN B-12 (431 patients)
DEXAMETHASONE TAB (430 patients)
ALDACTONE (429 patients)
PANTOPRAZOLE SODIUM (424 patients)
NEULASTA (423 patients)
NEORAL (419 patients)
LANTUS (419 patients)
DEPAKENE (416 patients)
PROCRIT (403 patients)
CELEBREX (400 patients)
ZANTAC (395 patients)
TAXOL (395 patients)
NITROGLYCERIN (392 patients)
VITAMIN D (390 patients)
CAPECITABINE (389 patients)
ROCEPHIN (388 patients)
ALIMTA (382 patients)
SPIRONOLACTONE (382 patients)
DURAGESIC-100 (380 patients)
ZYPREXA (378 patients)
MORPHINE SULFATE (378 patients)
BEVACIZUMAB (373 patients)
LEVOFLOXACIN (370 patients)
FERROUS SULFATE TAB (365 patients)
COREG (361 patients)
COLACE (361 patients)
LEXAPRO (361 patients)
HUMIRA (357 patients)
MYCOPHENOLATE MOFETIL (356 patients)
LEUCOVORIN CALCIUM (356 patients)
EPOGEN (355 patients)
AMOXICILLIN (353 patients)
COPEGUS (351 patients)
FLAGYL (350 patients)
LOPRESSOR (348 patients)
METOPROLOL (346 patients)
DILAUDID (345 patients)
CETUXIMAB (343 patients)
DIOVAN (338 patients)
METRONIDAZOLE (338 patients)
MAGNESIUM OXIDE (336 patients)
CALCIUM CARBONATE (336 patients)
ADRIAMYCIN PFS (333 patients)
REOPRO (332 patients)
MABTHERA (330 patients)
RADIATION THERAPY (328 patients)
CYTOXAN (327 patients)
DEPAKOTE (326 patients)
TRAMADOL HCL (325 patients)
METOCLOPRAMIDE (325 patients)
PROGRAF (324 patients)
LORTAB (324 patients)
TEMOZOLOMIDE (323 patients)
PEPCID (323 patients)
PAXIL (323 patients)
TASIGNA (321 patients)
LACTULOSE (319 patients)
ALPRAZOLAM (318 patients)
NYSTATIN (316 patients)
VALTREX (316 patients)
CLONAZEPAM (314 patients)
NEXAVAR (314 patients)
MELPHALAN HYDROCHLORIDE (313 patients)
CITALOPRAM HYDROBROMIDE (313 patients)
ENALAPRIL MALEATE (309 patients)
CLOPIDOGREL (308 patients)
CALCIUM (307 patients)
REGLAN (304 patients)
TAXOTERE (304 patients)
TEMODAL (301 patients)
DOCETAXEL (301 patients)
SUNITINIB MALATE (299 patients)
SODIUM CHLORIDE (296 patients)
VALPROATE SODIUM (295 patients)
PARACETAMOL (295 patients)
CRESTOR (294 patients)
RITUXAN (291 patients)
ACCUTANE (290 patients)
MS CONTIN (288 patients)
THALOMID (284 patients)
IRINOTECAN HCL (283 patients)
HYDROCORTISONE (282 patients)
KYTRIL (280 patients)
LAMICTAL (278 patients)
BISOPROLOL FUMARATE (278 patients)
ASCORBIC ACID (277 patients)
CARVEDILOL (277 patients)
TEGRETOL (274 patients)
XIGRIS (270 patients)
CLINDAMYCIN (268 patients)
COZAAR (268 patients)
GLUCOPHAGE (267 patients)
IFOSFAMIDE (266 patients)
EFFEXOR (266 patients)
MIRALAX (264 patients)
Most common side effects for patients taking ALIZAPRIDE:
DIARRHOEA (16 patients)
PYREXIA (16 patients)
VOMITING (10 patients)
FATIGUE (9 patients)
HYPOKALAEMIA (9 patients)
DEHYDRATION (8 patients)
NAUSEA (7 patients)
ANAEMIA (6 patients)
ASTHENIA (6 patients)
BRONCHOPNEUMONIA (6 patients)
DRUG INTERACTION (6 patients)
DYSPNOEA (6 patients)
HYPOTENSION (6 patients)
PNEUMONIA (6 patients)
GENERAL PHYSICAL HEALTH DETERIORATION (5 patients)
HAEMORRHAGE (5 patients)
HYPOMAGNESAEMIA (5 patients)
HYPOPHOSPHATAEMIA (5 patients)
JAUNDICE (5 patients)
RESPIRATORY FAILURE (5 patients)
SOMNOLENCE (5 patients)
TACHYCARDIA (5 patients)
ABDOMINAL PAIN (4 patients)
ADVERSE DRUG REACTION (4 patients)
FALL (4 patients)
HAEMODIALYSIS (4 patients)
HAEMOGLOBIN DECREASED (4 patients)
INTESTINAL OBSTRUCTION (4 patients)
MALAISE (4 patients)
SLEEP APNOEA SYNDROME (4 patients)
SUPRAVENTRICULAR TACHYCARDIA (4 patients)
THROMBOCYTHAEMIA (4 patients)
THROMBOCYTOPENIA (4 patients)
WHITE BLOOD CELL COUNT DECREASED (4 patients)
ACUTE RESPIRATORY DISTRESS SYNDROME (3 patients)
BACTERIAL SEPSIS (3 patients)
BLOOD BILIRUBIN INCREASED (3 patients)
BLOOD CREATININE INCREASED (3 patients)
DECREASED APPETITE (3 patients)
DERMATITIS EXFOLIATIVE (3 patients)
DEVICE DISLOCATION (3 patients)
ENTERITIS (3 patients)
FEBRILE NEUTROPENIA (3 patients)
FIBRIN D DIMER INCREASED (3 patients)
FUSOBACTERIUM INFECTION (3 patients)
HAEMOPTYSIS (3 patients)
HYPOXIA (3 patients)
ILEUS (3 patients)
LEUKAEMIA RECURRENT (3 patients)
MUCOSAL INFLAMMATION (3 patients)
NEUROTOXICITY (3 patients)
NEUTROPENIA (3 patients)
OVERDOSE (3 patients)
PRESYNCOPE (3 patients)
PROTEUS INFECTION (3 patients)
RASH (3 patients)
RENAL FAILURE ACUTE (3 patients)
SEPTIC SHOCK (3 patients)
SUPERINFECTION (3 patients)
TONGUE DISORDER (3 patients)
ACUTE PULMONARY OEDEMA (2 patients)
AGRANULOCYTOSIS (2 patients)
ATRIAL FIBRILLATION (2 patients)
BLOOD FIBRINOGEN INCREASED (2 patients)
BLOOD GLUCOSE INCREASED (2 patients)
BONE MARROW DEPRESSION (2 patients)
BONE MARROW FAILURE (2 patients)
BRONCHOPULMONARY ASPERGILLOSIS (2 patients)
C-REACTIVE PROTEIN INCREASED (2 patients)
CHILLS (2 patients)
COLITIS ISCHAEMIC (2 patients)
CONSTIPATION (2 patients)
CONVULSION (2 patients)
CORONARY ARTERY DISEASE (2 patients)
DEAFNESS (2 patients)
DIZZINESS (2 patients)
DRUG ADMINISTRATION ERROR (2 patients)
DYSPHAGIA (2 patients)
DYSURIA (2 patients)
EJECTION FRACTION DECREASED (2 patients)
ERYSIPELAS (2 patients)
FACIAL PALSY (2 patients)
FEBRILE BONE MARROW APLASIA (2 patients)
FLATULENCE (2 patients)
GASTROENTERITIS (2 patients)
HAEMATOCRIT DECREASED (2 patients)
HYPERSENSITIVITY (2 patients)
INAPPROPRIATE ANTIDIURETIC HORMONE SECRETION (2 patients)
INFECTION (2 patients)
KLEBSIELLA SEPSIS (2 patients)
LEUKOPENIA (2 patients)
LYMPHANGITIS (2 patients)
LYMPHOCYTE COUNT INCREASED (2 patients)
NERVOUS SYSTEM DISORDER (2 patients)
NEUTROPHIL COUNT DECREASED (2 patients)
OEDEMA MUCOSAL (2 patients)
OTITIS MEDIA (2 patients)
PANCYTOPENIA (2 patients)
PARTIAL SEIZURES (2 patients)
PLATELET COUNT DECREASED (2 patients)
PULMONARY EMBOLISM (2 patients)
RED BLOOD CELL COUNT DECREASED (2 patients)
RENAL FAILURE (2 patients)
RHINORRHOEA (2 patients)
SHOCK (2 patients)
STREPTOCOCCAL SEPSIS (2 patients)
SUDDEN CARDIAC DEATH (2 patients)
URTICARIA (2 patients)
ACCIDENTAL OVERDOSE (1 patients)
ACUTE GRAFT VERSUS HOST DISEASE IN INTESTINE (1 patients)
ACUTE GRAFT VERSUS HOST DISEASE IN SKIN (1 patients)
AGITATION (1 patients)
ALVEOLITIS (1 patients)
ANOREXIA (1 patients)
ANXIETY (1 patients)
APHASIA (1 patients)
APHTHOUS STOMATITIS (1 patients)
ARACHNOIDITIS (1 patients)
BLOOD CULTURE POSITIVE (1 patients)
CALCULUS URINARY (1 patients)
CANDIDA SEPSIS (1 patients)
CANDIDIASIS (1 patients)
CARDIO-RESPIRATORY ARREST (1 patients)
CENTRAL NERVOUS SYSTEM LEUKAEMIA (1 patients)
CEREBRAL HAEMORRHAGE (1 patients)
CHEST PAIN (1 patients)
COLITIS (1 patients)
CONFUSIONAL STATE (1 patients)
COUGH (1 patients)
CYANOSIS (1 patients)
DIARRHOEA INFECTIOUS (1 patients)
DISEASE PROGRESSION (1 patients)
DISLOCATION OF VERTEBRA (1 patients)
DOCUMENTED HYPERSENSITIVITY TO ADMINISTERED DRUG (1 patients)
DRUG HYPERSENSITIVITY (1 patients)
DRUG TOXICITY (1 patients)
DRY SKIN (1 patients)
ENCEPHALOPATHY (1 patients)
EPILEPSY (1 patients)
ERYTHEMA (1 patients)
FLUSHING (1 patients)
GAMMA-GLUTAMYLTRANSFERASE INCREASED (1 patients)
GENERAL PHYSICAL CONDITION ABNORMAL (1 patients)
GRAFT VERSUS HOST DISEASE (1 patients)
HAEMATURIA (1 patients)
HEADACHE (1 patients)
HYPERBILIRUBINAEMIA (1 patients)
HYPERTENSIVE CRISIS (1 patients)
HYPOACUSIS (1 patients)
HYPOAESTHESIA (1 patients)
HYPOCALCAEMIA (1 patients)
HYPOMANIA (1 patients)
HYPOVOLAEMIC SHOCK (1 patients)
KLEBSIELLA INFECTION (1 patients)
LACTOSE INTOLERANCE (1 patients)
LEUKAEMIA PLASMACYTIC (1 patients)
METASTATIC NEOPLASM (1 patients)
MULTI-ORGAN FAILURE (1 patients)
MULTIPLE MYELOMA (1 patients)
MUSCULAR WEAKNESS (1 patients)
MYALGIA (1 patients)
MYOGLOBIN BLOOD INCREASED (1 patients)
NEOPLASM (1 patients)
NEURALGIA (1 patients)
OEDEMA (1 patients)
OEDEMA PERIPHERAL (1 patients)
PAIN (1 patients)
PARESIS (1 patients)
PNEUMONIA KLEBSIELLA (1 patients)
PNEUMONITIS (1 patients)
PRODUCTIVE COUGH (1 patients)
PRURITUS (1 patients)
PULMONARY ALVEOLAR HAEMORRHAGE (1 patients)
PULMONARY HYPERTENSION (1 patients)
RADIUS FRACTURE (1 patients)
RASH GENERALISED (1 patients)
RASH MACULAR (1 patients)
RASH MACULO-PAPULAR (1 patients)
RENAL COLIC (1 patients)
RESPIRATORY DISTRESS (1 patients)
RIGHT VENTRICULAR DYSFUNCTION (1 patients)
SEPSIS (1 patients)
SKIN LESION (1 patients)
SPUTUM PURULENT (1 patients)
STAPHYLOCOCCAL BACTERAEMIA (1 patients)
STEM CELL TRANSPLANT (1 patients)
STOMATITIS (1 patients)
THROMBOSIS (1 patients)
THROMBOTIC MICROANGIOPATHY (1 patients)
TOXICITY TO VARIOUS AGENTS (1 patients)
ULNA FRACTURE (1 patients)
WEIGHT DECREASED (1 patients)

In addition to reviewing our up-to-date FDA research, users may interact with the FactMed community - currently one million members and growing! FactMed online research and discussions are read by patients, scientists, physicians, and other interested health care parties. Post follow up Questions to learn from our diverse readership. Likewise, patients who have experienced unwanted effects are encouraged to share their Concerns to help educate and inform our members.


Recent FactMed Activity for ALIZAPRIDE


Issue Description / Topic Timestamp

My Patient Resources

Get your questions answered! Over one million patients, researchers, and health care providers have visited FactMed. If you have a question about THROMBOCYTOPENIA and ALIZAPRIDE, post it here. You may receive a response from a fellow patient - or a leading expert in the field.
Your Question:

Share your experience: Over one million patients, researchers, and health care providers have visited FactMed. If you have a noteworthy experience as a patient taking ALIZAPRIDE, post it here. Your story could help a fellow patient - or provide insight to a leading expert in the field.
Your Experience or Concern:

Telemedicine Expert Consults FactMed newest feature allows patients to consult - via realtime videoconferencing - experts in ALIZAPRIDE. This premium feature connects patients to experts, regardless of geography. FactMed experts charge reasonable rates that may be reimbursable by your insurance as a second-opinion.
We are currently accepting registration for ALIZAPRIDE experts. If you are a healthcare provider experienced in prescribing ALIZAPRIDE, please register here.

Your online appointment book for Conroe Rentals & Services

© 2014 FactMed, Inc
Privacy Policy
Terms of Use